ATOSSA THERAPEUTICS, INC. ATOS
We are a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer and other breast conditions. Our lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator (SERM)/ selective estrogen receptor degrader (SERM/D) currently in Phase 2 clinical development. The Company is evaluating potential indications for (Z)-endoxifen based on its pharmacologic profile, including its potential for both reducing the risk of and for the treatment of breast cancer, as well as in other therapeutic areas.
We have been granted U.S. and international patents covering our proprietary (Z)-endoxifen, and we have numerous applications pending in the U.S. and in other major countries. We expect to have patent protection covering our proprietary (Z)-endoxifen through at least November 17, 2038.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $21.2M | $14.1M | $17.3M | $15.1M | $9.2M | $6.6M | $6.6M | $4.2M | $2.3M | $770.4K |
| SG&A | $16.0M | $13.5M | $14.0M | $12.6M | $11.3M | $8.0M | $10.6M | $7.2M | $4.9M | $6.5M |
| Total operating expenses | $37.1M | $27.6M | $31.4M | $27.7M | $20.5M | $14.6M | $17.3M | $11.4M | $7.6M | $8.0M |
| Operating income | -$37.1M | -$27.6M | -$31.4M | -$27.7M | -$20.5M | -$14.6M | -$17.3M | -$11.4M | -$7.6M | -$8.0M |
| Pre-tax income | -$34.8M | -$25.5M | -$30.1M | -$27.0M | -$20.6M | -$17.8M | -$17.2M | -$11.4M | -$8.1M | -$6.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$34.8M | -$25.5M | -$30.1M | -$27.0M | -$20.6M | -$17.8M | -$17.2M | -$11.4M | -$8.1M | -$6.4M |
| EPS, basic | -4.04 | -3.04 | -0.24 | -0.21 | -0.18 | — | — | — | — | — |
| EPS, diluted | -4.04 | -3.04 | -0.24 | -0.21 | -0.18 | -1.97 | -2.03 | -5.50 | -10.97 | -2.16 |
| Shares, diluted (wtd. avg.) | $8.6M | $8.4M | $126.1M | $126.6M | $117.0M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $41.3M | $71.1M | $88.5M | $110.9M | $136.4M | $39.6M | $12.6M | $10.4M | $7.2M | $3.0M |
| Total current assets | $45.6M | $74.5M | $92.2M | $118.2M | $141.2M | $42.8M | $14.3M | $11.5M | $7.9M | $3.3M |
| Property, plant and equipment | — | — | — | — | $20.0K | $21.0K | $34.4K | $54.5K | $11.5K | $55.1K |
| Other intangibles | — | — | — | — | $54.0K | $41.0K | $173.5K | $192.0K | $234.0K | $640.4K |
| Total assets | $47.6M | $76.4M | $96.3M | $123.5M | $141.3M | $42.8M | $14.5M | $11.7M | $8.2M | $4.1M |
| Accounts payable | $4.3M | $679.0K | $806.0K | $3.0M | $1.7M | $1.6M | $293.2K | $353.3K | $334.9K | $254.3K |
| Total current liabilities | $8.3M | $5.0M | $5.2M | $5.6M | $3.1M | $15.7M | $1.3M | $2.9M | $1.2M | $1.0M |
| Total liabilities | $8.3M | $5.0M | $5.2M | $5.6M | $3.1M | $15.7M | $1.3M | $2.9M | — | $1.0M |
| Retained earnings | -$246.6M | -$211.8M | -$186.3M | -$156.2M | -$129.2M | -$111.9M | -$94.1M | -$76.8M | -$65.4M | -$57.3M |
| Total equity | $39.4M | $71.5M | $91.0M | $118.0M | $138.1M | $27.2M | $13.2M | $8.8M | $6.9M | $3.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.8M | -$21.0M | -$20.9M | -$20.8M | -$16.5M | -$11.6M | -$9.1M | -$9.0M | -$6.6M | -$5.4M |
| Depreciation and amortisation | $16.0K | $17.0K | $23.0K | $8.0K | $23.0K | $47.0K | $52.8K | $44.2K | $129.0K | $303.5K |
| Stock-based compensation | $2.6M | $2.3M | $4.6M | $6.8M | — | — | — | — | — | — |
| Capital expenditure | $23.0K | $19.0K | $14.0K | $27.0K | $9.0K | $9.0K | $7.6K | $110.9K | — | — |
| Investing cash flow | -$23.0K | -$19.0K | -$14.0K | -$4.7M | -$9.0K | -$9.0K | -$7.6K | -$110.9K | — | -$9.2K |
| Financing cash flow | $0 | $3.7M | -$1.5M | $0 | $113.3M | $38.6M | $11.3M | $12.3M | $10.8M | $4.7M |
| Buybacks | — | $0 | $1.5M | $0 | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-124396.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |